Key Takeaways KYMR started dosing in the phase IIb BREADTH study of KT-621 for eosinophilic asthma.KYMR's asthma study tests three doses of KT-621 in adults over 12 weeks, with FEV1 as the primary endpoint.KYMR is also running another phase IIb AD study of KT-621, with asthma data due in late 2027.Kymera Therapeutics (KYMR) announced that it has begun dosing patients in the phase IIb BREADTH study of KT-621 for moderate-to-severe eosinophilic asthma. KT-621 is an investigational, first-in-class, once-daily, ...

Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027 WATERTOWN, Mass., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it recently initiated dosing in its BREADTH Phase 2b clinical tri ...

Kymera Therapeutics, Inc. (NASDAQ:KYMR) is among the 14 best booming stocks to buy right now. Its shares have gained over 28% in the last three months, with Wall Street anticipating a further uptick of nearly 60%, as of the close of business on January 12. Kymera Therapeutics, Inc. (KYMR) Up 28% in 3M, Analysts See Further Upside However, on January 6, Wolfe Research downgraded the stock to Peer Perform from Outperform, and according to a report on TipRanks, the firm also removed its $92 price target for ...

Group 1 - The article discusses the importance of enabling Javascript and cookies in browsers to prevent access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1]

PresentationGood morning, everyone. Thanks for joining us for another session at the 44th JPMorgan Healthcare Conference. I'm Brian Cheng, one of the senior biotech analysts here at the firm. On stage, we have the CEO from Kymera Therapeutics, Nello Mainolfi. I'll now pass the mic to their CEO for a short presentation, followed by a live audience Q&A.Nello MainolfiCo-Founder, President, CEO & Director Thanks, Brian. Thanks, everybody, for joining us. Hopefully, the sound is good. Always great to be at JPMor ...

Kymera Therapeutics (NasdaqGM:KYMR) FY Conference January 13, 2026 12:00 PM ET Company ParticipantsNello Mainolfi - CEOConference Call ParticipantsNone - Analyst 2Brian Cheng - Senior Biotech AnalystNone - Analyst 1Brian ChengGood morning, everyone. Thanks for joining us for another session at the 44th J.P. Morgan Healthcare Conference. I'm Brian Chang. I'm one of the senior biotech analysts here at the firm. On stage, we have the CEO from Kymera Therapeutics, Nello Mainolfi. I'll now pass the mic to their ...

Kymera's Strategy and Pipeline - Kymera is focused on developing oral degrader medicines with biologics-like activity to transform immunology treatments[7, 16] - The company's pipeline includes KT-621 (STAT6 degrader), KT-579 (IRF5 degrader), and KT-485 (IRAK4 degrader), targeting various immunological diseases[27] - Kymera expects to report Phase 2b AD study data by mid-2027 and Phase 2b asthma study data in late-2027 for KT-621[27, 92] - A Phase 1 healthy volunteer trial for KT-579 is expected to initiate in Q1 2026, with data reported in 2H 2026[27, 92] - Sanofi plans to advance KT-485 into a Phase 1 clinical trial in 2026[14, 91] KT-621 Clinical Data and Market Opportunity - KT-621 has shown deep STAT6 degradation (>95%) in healthy volunteers and AD patients[44] - In the BroADen Phase 1b AD trial, KT-621 achieved significant reductions in EASI score (-63%), Total SCORAD (-48%), Peak Pruritus NRS (-40%), and SCORAD-Itch (-44%)[53, 54, 57] - KT-621 also demonstrated improvements in patient-reported outcomes, with 61% DLQI responders and 75% POEM responders[60] - KT-621 achieved a 56% median FeNO reduction in AD patients with comorbid asthma[71] - The potential patient impact for STAT6 inhibition in Type 2 inflammation is estimated to be >140 million, representing a >$20 billion market[35] Financial Position - Kymera is capitalized with $1.6 billion in cash, providing a runway into 2029[14]

Financial Position - Kymera Therapeutics has $1.6 billion in cash, providing a runway into 2029[1] Clinical Trials - The KT-621 BROADEN2 Phase 2b trial in atopic dermatitis (AD) is ongoing, with data expected by mid-2027, and the trial includes approximately 200 patients[6] - The KT-621 BREADTH Phase 2b trial in asthma has been initiated, with data expected in late-2027, involving approximately 264 adult patients[6] - KT-621 received FDA Fast Track designation for the treatment of moderate to severe AD in December 2025[6] - In December 2025, KT-621 demonstrated significant reductions in Type 2 inflammatory biomarkers and improvements in clinical endpoints in a Phase 1b trial[6] - The primary endpoint for the BROADEN2 trial is the percent change from baseline in Eczema Area and Severity Index (EASI) score at week 16[6] - The primary endpoint for the BREADTH trial is the percent change from baseline in pre-bronchodilator forced expiratory volume in one second (FEV1)[6] Development Pipeline - The company plans to advance at least one new development candidate towards IND for a first-in-class oral immunology program in 2026[10] - KT-579, an investigational oral degrader, is expected to initiate its first-in-human Phase 1 trial in Q1 2026, with data anticipated in the second half of 2026[9] Strategic Vision - Kymera aims to reshape the treatment of common immuno-inflammatory diseases with its innovative oral therapies[2]

KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027 KT-579 Phase 1 HV clinical trial expected to start in 1Q26, with data expected in 2H26 Advancing at least one new development candidate towards IND for a first-in-class, oral immunology program in 2026 Well-capitalized with $1.6 billion1 in cash and runway into 2029 Kymera to present its 2026 objectives at the J.P. Morgan 44th Annual Healthcare Co ...

Kymera Therapeutics, Inc. (KYMR) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power ...